HomeCompareRRGI vs ABBV

RRGI vs ABBV: Dividend Comparison 2026

RRGI yields 10000000.00% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RRGI wins by $4.762052817831319e+46M in total portfolio value
10 years
RRGI
RRGI
● Live price
10000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.762052817831319e+46M
Annual income
$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00
Full RRGI calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — RRGI vs ABBV

📍 RRGI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRRGIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RRGI + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RRGI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RRGI
Annual income on $10K today (after 15% tax)
$850,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$40,476,652,714,542,950,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, RRGI beats the other by $40,476,652,714,542,950,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RRGI + ABBV for your $10,000?

RRGI: 50%ABBV: 50%
100% ABBV50/50100% RRGI
Portfolio after 10yr
$2.3810264089156593e+46M
Annual income
$23,809,795,714,437,028,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RRGI
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RRGI buys
0
ABBV buys
0
No recent congressional trades found for RRGI or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRRGIABBV
Forward yield10000000.00%3.09%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.762052817831319e+46M$103.7K
Annual income after 10y$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00$25,324.79
Total dividends collected$4.762046689458665e+46M$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RRGI vs ABBV ($10,000, DRIP)

YearRRGI PortfolioRRGI Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,000,010,700$1,000,000,000.00$11,555$434.96+$1000.00MRRGI
2$93,460,013,936,683$93,458,943,925,233.62$13,485$635.47+$93460013.92MRRGI
3$8,163,259,573,940,183,000$8,163,159,571,725,270,000.00$15,933$937.67+$8163259573940.17MRRGI
4$666,373,880,559,373,300,000,000$666,365,145,871,629,100,000,000.00$19,118$1,400.80+$666373880559373312.00MRRGI
5$50,838,057,311,279,720,000,000,000,000$50,837,344,291,227,520,000,000,000,000.00$23,384$2,125.24+$5.083805731127972e+22MRRGI
6$3,624,737,622,195,432,400,000,000,000,000,000$3,624,683,225,474,109,500,000,000,000,000,000.00$29,290$3,286.81+$3.6247376221954326e+27MRRGI
7$241,535,451,261,763,920,000,000,000,000,000,000,000$241,531,572,792,508,160,000,000,000,000,000,000,000.00$37,776$5,205.38+$2.4153545126176394e+32MRRGI
8$15,041,872,435,857,020,000,000,000,000,000,000,000,000,000$15,041,613,992,924,168,000,000,000,000,000,000,000,000,000.00$50,495$8,488.44+$1.504187243585702e+37MRRGI
9$875,466,765,540,973,800,000,000,000,000,000,000,000,000,000,000$875,450,670,737,467,500,000,000,000,000,000,000,000,000,000,000.00$70,497$14,346.44+$8.754667655409739e+41MRRGI
10$47,620,528,178,313,184,000,000,000,000,000,000,000,000,000,000,000,000$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00$103,718$25,324.79+$4.762052817831319e+46MRRGI

RRGI vs ABBV: Complete Analysis 2026

RRGIStock

Reality Racing Inc. is a development stage company and produces original programming relating to stock car racing. Its television show, Reality Racing-The Rookie Challenge, combines reality television and stockcar racing that is aired in the United States and its territories, as well as in Canada. The company also offers T-shirts for men; T-shirts and yoga pants for women; caps; and beer mugs, picnic coolers, stadium blankets, and umbrellas through online stores. The company was formerly known as Yellowbubble.com, Inc. and changed its name to Reality Racing Inc. in August 2005. The company is based in Boca Raton, Florida.

Full RRGI Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RRGI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RRGI vs SCHDRRGI vs JEPIRRGI vs ORRGI vs KORRGI vs MAINRRGI vs JNJRRGI vs MRKRRGI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.